<DOC>
	<DOCNO>NCT00949052</DOCNO>
	<brief_summary>RATIONALE : Identifying gene increase person 's susceptibility second cancer may help study cancer treatment . PURPOSE : This study look genetic susceptibility risk second cancer patient undergone stem cell transplant cancer .</brief_summary>
	<brief_title>Genetic Susceptibility Risk Second Cancers Patients Who Have Undergone Stem Cell Transplant Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether genetic susceptibility ( e.g. , inherited difference radiation sensitivity normal tissue gene xenobiotic metabolism , nucleotide provision , DNA repair ) carcinogenic effect radiotherapy , tobacco , UV light modifies risk second malignant neoplasm ( SMN ) patient cancer treat hematopoietic stem cell transplantation ( HSCT ) . Secondary - Measure inherent sensitivity radiotherapy via G_2 chromosome radiation sensitivity assay use B-cell lymphoblastoid cell line derive pre-HSCT cryopreserved peripheral blood mononuclear cell patient without SMN . - Measure frequency allelic variant gene involve xenobiotics metabolism , DNA repair , provision nucleotide pool compare frequency among patient without SMN , determine transmission specific allele gene parent patient , correlate allelic variant DNA repair nucleotide provision gene vitro radiation sensitivity . - Evaluate role potentially carcinogenic environmental exposure ( tobacco sun light ) pre- post-HSCT risk SMN examine association exposures SMN interaction exposures allelic variant gene involve xenobiotic metabolism , nucleotide provision , DNA repair . OUTLINE : Patients complete self-reported questionnaire medical record review collect information UV light tobacco exposure pre- post-transplantation . Information analyze association second malignancy neoplasm . Blood sample collect patient pre-hematopoietic stem cell transplantation parent ( available ) first-degree relative genetic biomarkers susceptibility second malignancy , DNA repair provision nucleotide , genetic susceptibility toxicity combine cancer therapy , environmental carcinogen . PROJECTED ACCRUAL : A total 1,000 patient ( 800 patient without second malignant neoplasm [ SMN ] 200 patient SMN ) accrue study .</detailed_description>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>CASES : Survived least 100 day posthematopoietic stem cell transplantation ( HSCT ) . Developed SMN time point . And receive TBI part preparative regimen . CONTROLS randomly select : In 4:1 ratio case cohort 100 day + survivor HSCT receive TBI . Controls match case race primary diagnosis . In addition , must survive least elapsed time case 's HSCT secondary cancer , without development SMN . We match primary diagnosis , genotype radiation sensitivity may predispose specific primary cancer , well SMNs . We match race , allele frequency vary widely across ethnic group . Did survive least 100 day posthematopoietic stem cell transplantation ( HSCT ) . Did develop SMN time point . Did receive TBI part preparative regimen .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>cancer survivor</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>